1. Home
  2. GLAD vs ZURA Comparison

GLAD vs ZURA Comparison

Compare GLAD & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gladstone Capital Corporation

GLAD

Gladstone Capital Corporation

HOLD

Current Price

$18.59

Market Cap

395.6M

Sector

Finance

ML Signal

HOLD

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$5.71

Market Cap

521.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLAD
ZURA
Founded
2001
2022
Country
United States
United States
Employees
65
30
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
395.6M
521.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GLAD
ZURA
Price
$18.59
$5.71
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$22.33
$13.00
AVG Volume (30 Days)
237.7K
593.9K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
9.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.16
N/A
Revenue Next Year
$5.10
N/A
P/E Ratio
$11.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.54
$0.99
52 Week High
$29.50
$7.25

Technical Indicators

Market Signals
Indicator
GLAD
ZURA
Relative Strength Index (RSI) 57.14 45.02
Support Level $16.54 $5.35
Resistance Level $18.94 $5.75
Average True Range (ATR) 0.56 0.39
MACD 0.14 -0.01
Stochastic Oscillator 84.73 40.57

Price Performance

Historical Comparison
GLAD
ZURA

About GLAD Gladstone Capital Corporation

Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Share on Social Networks: